As would be expected in a MAPK-driven tumor model, MEK1/2 inhibition with AZD6244 resulted in dramatic remodeling of the transcriptional landscape, which was contrasted with the minimal impact of p110α (AZD8835) or p110β/δ (AZD8186) monotherapy (Supplementary Fig. S10A). This evidence concerns the gene MAP2K1 and neoplasm.